Last updated on May 2020

Safety Efficacy and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors


Brief description of study

This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BOS172738.

Clinical Study Identifier: NCT03780517

Find a site near you

Start Over

UZ Leuven

Leuven, Belgium
  Connect »

City of Hope

Duarte, CA United States
  Connect »

Fox Chase Cancer Center

Philadelphia, PA United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.